United StatesHealth

Invivyd (NASDAQ:IVVD) reported preliminary fourth-quarter net product revenue of $17.2 million for its COVID-19 antibody, PEMGARDA.

The figure marks a 25% increase over the same period last year and a 31% sequential jump from the third quarter.

NervGen Pharma Corp. (NASDAQ:NGEN) officially began trading on the Nasdaq Stock Market on January 8, marking a transition into a late-stage biopharmaceutical player.

Organon (NYSE:OGN) has entered a strategic agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid), a first-in-class treatment for high cholesterol, across France, Denmark, Iceland, Sweden, Finland, and Norway.

Pharming Group N.V. (NASDAQ:PHAR) reported preliminary, unaudited full-year 2025 revenues of approximately $376 million, topping its own recently elevated guidance and marking a 27% increase over 2024.

Evotec SE (NASDAQ:EVO) announced that its Seattle-based subsidiary, Just – Evotec Biologics, has received a new grant (INV072135) from the Bill & Melinda Gates Foundation to accelerate the development of affordable biologics for low- and middle-income countries.

New US dietary guidelines place protein and whole foods at the centre of federal nutrition policy.

OpenAI’s rollout of ChatGPT Health has raised fresh questions over how sensitive medical data is protected.

Oculis Holding AG (NASDAQ:OCS) is set to showcase its late-stage ophthalmology pipeline at the 44th Annual J.P. Morgan Healthcare Conference on January 14, following a pivotal start to the year.

Genprex (NASDAQ:GNPX) issued a clinical update on January 7, 2026, for its diabetes gene therapy program, highlighting significant preclinical progress and regulatory advancements for GPX-002.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS).

Merck & Co. (NYSE:MRK) began a late-stage clinical trial for a new combination therapy aimed at untreated lung cancer, seeking to eliminate the need for traditional chemotherapy and intravenous infusions for patients with a specific genetic mutation.

Merck & Co. (NYSE:MRK) completed its acquisition of Cidara Therapeutics on Wednesday, following a successful tender offer that values the biotechnology firm at approximately $9 billion.